AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$INCY

CAGNONI PABLO J sold $1.4M of INCY

CAGNONI PABLO J (President, Global Head of R&D) sold 10,801 shares of INCYTE CORP (INCY) at $125.56 ($1.36M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAGNONI PABLO J
Published Aug 20, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INCY
Bearish
medium confidence
Mentioned
$INCY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYBearishLow
01

Why it matters

The disclosed sale provides fresh information on insider sentiment, which can influence short‑term trading decisions.

02

Market read

First‑report insider sale; may affect INCY's stock price in the near term.

03

What to watch

The insider retains 183,200 shares, representing a substantial stake that may temper negative sentiment.

Relevance 5/10Novelty 6/10Timing: post‑market today

Background

SEC Form 4 filing discloses an insider transaction for INCYTE Corp (NASDAQ: INCY).

Company-level read

Ticker impact

$INCYBearishMedium confidence
Context

President Pablo Cagnoni sold 10,801 shares for $1.36M via a 10b5‑1 plan on 2026‑08‑19.

Expected impact

Potential short‑term dip of 2‑4% as market digests the sale.

Evidence & confidence

The sale size is modest relative to float, but the insider's senior role and use of a pre‑arranged plan suggest a material signal.

Market effects

Sector

Minimal impact on the biotech sector; insider activity is company‑specific.

Regional

No broader regional effect.

Global

Limited to investors tracking INCY.

Counterpoint

What could challenge this read

The sale may be purely portfolio rebalancing under a 10b5‑1 plan, not a bearish signal.

Key entities

  • Officer
    Pablo Cagnoni

    President, Global Head of R&D at INCY

  • Company
    INCYTE Corp

    Biotech company listed on NASDAQ under ticker INCY

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INCY insider trading history →

Related articles

SEP 26
$MIRMHighAI 9/10

Mirum wins FDA Atebrioz approval for FOP patients 12+

Mirum Pharmaceuticals (MIRM) received FDA approval for Atebrioz to treat FOP in patients aged 12+. The drug, developed by Incyte (INCY), showed a reduction in new bone-lesion volume in a 63-patient study. U.S. availability is expected in October, with a patient support program in place. Mirum shares closed at $89.70, Incyte at $123.89 on Friday.

mugglehead.com3 min
SEP 25
$MIRMHighAI 9/10

Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.

finanznachrichten.de3 min
SEP 21
$INCYHighAI 8/10

EMA OKs Two Options for Refractory Inflammatory Conditions

The EMA's CHMP approved Povofortay (Incyte) for marketing to treat moderate to severe hidradenitis suppurativa (HS) in adults who failed anti-TNF therapy. It is the first oral option for HS, reducing pain and lesions. Cosentyx (Novartis) gained a new indication for polymyalgia rheumatica (PMR) in adults unresponsive to glucocorticoids. Both drugs showed efficacy in clinical trials.

medscape.com2 min